Polygenic Risk Scores for Heart Disease: What the New 2026 ACC/AHA Guidelines Actually Say

Genetic testing is becoming increasingly common in preventive medicine, and cardiovascular care is no exception. The 2026 ACC/AHA multisociety guideline on the management of dyslipidemia gives new visibility to polygenic risk scores for coronary artery disease, identifying high polygenic risk as one of the factors that may enhance cardiovascular risk assessment when it has been measured.

That is an interesting development. It does not necessarily mean that everyone needs another genetic test.

What Is a Polygenic Risk Score?

Much of the genetic testing familiar to patients looks for a particular variant associated with a particular disease or biological pathway. Polygenic risk scoring takes a different approach. Coronary artery disease is influenced by many genetic variants, most of which individually have only a small effect. A polygenic risk score combines information from a large number of these variants and uses statistical models to estimate how a person's inherited susceptibility compares with that of a reference population.

This can reveal something that a standard cholesterol panel cannot. Two people with similar LDL cholesterol, blood pressure and glucose may not have the same inherited tendency to develop coronary disease. That difference may help explain why cardiovascular disease sometimes appears unusually early in families even when the conventional risk profile does not initially look dramatic.

The science has advanced considerably as genome-wide association studies have become larger and the models used to construct polygenic scores have improved. The 2026 guideline notes that coronary artery disease PRS can improve risk prediction beyond clinical and demographic factors alone and that newer multi-ancestry approaches have improved performance across populations. It also notes that the effect of a high PRS appears particularly pronounced in adults younger than 55 and that high polygenic risk is more common among people with a family history of premature coronary artery disease.

What the 2026 ACC/AHA Guideline Actually Says

The inclusion of polygenic risk in the guideline is meaningful, but the wording deserves attention. The guideline lists high polygenic risk, if measured, among cardiovascular risk-enhancing factors. It does not recommend routine PRS testing for every adult undergoing cardiovascular risk assessment.

The guideline also acknowledges limitations that are important in clinical practice. Not all coronary PRS models are equivalent. Different scores use different genetic datasets and methods and may produce different risk estimates for the same person. A low score from one model does not guarantee low inherited risk and certainly does not establish low overall cardiovascular risk.

There is nevertheless evidence supporting the underlying concept. The guideline cites analyses showing that people with high polygenic risk can experience greater relative and absolute benefit from lipid-lowering therapy, and it notes that a validated score associated with approximately a twofold increase in coronary risk is comparable in magnitude with other established risk-enhancing factors.

This makes PRS clinically credible. It still leaves physicians with a familiar problem: deciding when an additional piece of information is useful enough to obtain.

More Information Is Not Always More Useful Information

Preventive cardiology has become extraordinarily good at generating information. We can evaluate traditional lipids, ApoB, lipoprotein(a), glucose regulation, inflammatory markers when appropriate, blood pressure, body composition, family history and lifestyle risk. We can also look for evidence of atherosclerosis itself through carefully selected imaging.

The 2026 guideline continues this broader approach. It incorporates the newer PREVENT equations for primary prevention, recommends consideration of risk-enhancing factors, supports ApoB testing in selected patients and recommends that lipoprotein(a) be measured at least once in adulthood. When treatment decisions remain uncertain in appropriate borderline- or intermediate-risk patients, coronary artery calcium imaging can further refine risk.

Within a comprehensive preventive evaluation, those findings begin to create a much more complete cardiovascular picture than LDL cholesterol alone. If a patient already has clearly elevated ApoB, markedly elevated lipoprotein(a), a strong family history or evidence of atherosclerosis on imaging, a high polygenic risk score may help explain why the risk exists without necessarily altering what should be done about it.

A physician would still address atherogenic lipoprotein exposure. Blood pressure would still require appropriate management. Smoking, insulin resistance, physical inactivity, poor sleep and other modifiable contributors would still be addressed. Lipid-lowering therapy would still be considered according to the patient's overall risk and evidence of disease.

The reverse is also important. A favorable polygenic score should not provide false reassurance when stronger evidence points in the other direction. Someone with coronary plaque, significant carotid atherosclerosis or a markedly elevated ApoB does not become protected because a genetic model places that person in a lower percentile.

Where PRS May Be More Helpful

There are circumstances in which polygenic risk information could be quite useful. A younger adult with a striking family history of premature coronary disease but few abnormalities on conventional testing is one example. At younger ages, short-term risk calculators can appear reassuring simply because age carries so much weight in cardiovascular prediction, even when lifetime risk is developing in the background.

PRS may also help when a patient is near a clinical decision threshold and the physician and patient are trying to determine how aggressively or how early to intervene. In that setting, evidence of substantial inherited susceptibility could reasonably influence the discussion.

This is consistent with the direction of the new guideline, which increasingly emphasizes lifetime exposure and earlier prevention rather than waiting for conventional risk estimates to become obviously abnormal. The guideline lowers the starting age for formal PREVENT risk assessment to 30 and provides both 10-year and 30-year estimates, reflecting a broader effort to identify cardiovascular risk earlier in life.

For someone whose cardiovascular picture remains genuinely uncertain, another independent source of information may therefore have value. For someone whose risk has already been established through biomarkers, clinical history and imaging, the incremental benefit becomes less obvious.

What About Imaging?

Genetic susceptibility and atherosclerotic disease are related, but they are not the same thing. A PRS estimates inherited propensity. Imaging can sometimes tell us whether the disease process is already present.

That is one reason selective cardiovascular imaging remains so useful in preventive medicine. The 2026 guideline gives coronary artery calcium scoring a formal role when the decision about lipid-lowering therapy remains uncertain in appropriate patients. More detailed coronary imaging, including coronary CT angiography and plaque analysis in selected clinical circumstances, can provide additional information about actual coronary atherosclerosis rather than estimated susceptibility alone.

At HormoneSynergy®, cardiovascular risk assessment may include advanced lipid evaluation, ApoB, lipoprotein(a), metabolic assessment, VasoLabs® carotid ultrasound with CIMT and, when clinically appropriate, more advanced coronary imaging such as CCTA with Cleerly® plaque analysis. These tools are not interchangeable, and no single test determines cardiovascular risk by itself. They are selected according to the clinical question being asked.

For more information about this approach, see our Preventive Cardiology & Longevity Medicine resource and our comparison of Coronary Calcium Score vs. CCTA vs. Cleerly® Plaque Analysis.

Interesting Science, but Will It Change the Treatment Plan?

Polygenic risk scores deserve attention. Their appearance in the 2026 ACC/AHA guideline reflects a genuine advance in our ability to understand inherited cardiovascular susceptibility, and continued improvement in the science may make them increasingly useful in clinical medicine.

At the same time, preventive care does not improve simply by accumulating additional test results. Each test should answer a useful clinical question. When the result is likely to clarify an uncertain risk picture, influence the timing of treatment or materially change a prevention strategy, PRS testing may add something valuable. When a patient already has enough information to establish cardiovascular risk and guide treatment, another genetic risk estimate may provide greater detail without meaningfully changing care.

That is not an argument against genetic medicine. It is an argument for using genetic medicine thoughtfully. The purpose of precision medicine is not to measure everything that can be measured. It is to identify the information that helps physicians and patients make better decisions.

For patients interested in a broader evaluation of cardiovascular and longevity risk, the HormoneSynergy® Optimal Aging Assessment combines advanced laboratory testing, cardiovascular assessment, body composition, bone health and other measures within a physician-guided evaluation rather than treating any single biomarker as the whole story.

Sources

Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154-e1276. DOI: 10.1161/CIR.0000000000001423. Read the guideline.

American College of Cardiology. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol. March 13, 2026. Read the ACC summary.

This article is for educational purposes and is not intended to diagnose, treat or replace individualized medical care. Cardiovascular testing and treatment should be selected in consultation with a qualified healthcare professional based on personal history, examination, laboratory findings and other clinically relevant information.